Medipharm Labs Corp. · TSX:LABS
Medipharm Labs — Q3 2025 Earnings Presentation
21 slides from Medipharm Labs's earnings presentation, Nov 13, 2025
Slide 1: Investor Presentation Q3 2025
Investor Presentation Q3 2025 Pharmaceutical Quality Cannabis Products November 13th 2025 | medipharmlabs.com TSX: LABS | OTCQX : MEDIF | FSE: MLZ
Slide 2: Cautionary Notes
Cautionary Notes The information contained in this presentation (“Presentation”) of MediPharm Labs Corp. (“MediPharm”, the “Company”, “we”, “us”, or “our”) has been prepared for informational purposes only regarding the business of MediPharm and should be read together with the more detailed informa
Slide 3: A pharmaceutical company helping people feel better with cannabis
A pharmaceutical company committed to helping people feel better by unlocking the medical benefits of cannabis. 3
Slide 4: Company Highlights
Company Highlights Established Pharmaceutical Growing International Diverse Canadian Business Solid Financial Results Platform Medical Business • Innovative, premium product portfolio. • Q3 2025 revenue increased 17% • The first commercial natural extractor in • Q3 2025 83% growth year-over-year in
Slide 5: Uniquely Certified for Pharmaceutical Cannabis Industry
Uniquely Certified for Pharmaceutical Cannabis Industry DRUG ESTABLISHMENT LICENSE INTERNATIONAL GMP CANNABIS DRUG LICENSE Allows us to manufacture and sell API, Registered and inspected site with US FDA and Health Canada GMP Issued by Health Canada for the manufacture pharmaceutical drugs and nonst
Slide 6: Where MediPharm Labs Wins
Where MediPharm Labs Wins MediPharm is well positioned for success where regulations are strict, and compliance standards are most challenging. PHARMACEUTICAL CANNABIS INTERNATIONAL MEDICAL CANADIAN ADULT USE CANADIAN MEDICAL MARKET Market: Estimated sales of the major Market: Estimated value of $21
Slide 7: Our International Medical Cannabis Business
Our International Medical Cannabis Business GERMANY BRAZIL AUSTRALIA REST OF WORLD FY’25 market value estimate: $575 million FY’25 market value estimate: $200 million FY’25 market value estimate: $446 million MediPharm continues to expand global USD (Source: Prohibition Partners) USD million (Kaya M
Slide 8: Australian Medical Cannabis – Top Flower Sales in Australia
Australian Medical Cannabis – Top 5 Flower Sales in Australia Established in 2018, Beacon Medical is a leading medical cannabis brand in Australia. In 2023 the Beacon Medical portfolio was expanded to include GMP vapes and oils. The 2024 introduction of Beacon Select our line of premium flower and G
Slide 9: German Medical Cannabis
German Medical Cannabis As of April 1, 2024 Germany has decriminalized cannabis and it is no longer regulated as a narcotic, allowing for rapid expansion in the medical market. MediPharm has operated in Germany since 2019 and has three business lines in Germany. Beacon Medical GMBH Business to Busin
Slide 10: Canadian Medical
Canadian Medical MediPharm Labs is a leader in medical cannabis in Canada through our Canna Farms Medical platform, Harvest Medicine medical clinics and medical B2B product partnerships. MediPharm supports patients through their full journey, assisting thousands with direct access to physician consu
Slide 11: Canadian Adult Use & Wellness
Canadian Adult Use & Wellness MediPharm Labs delivers innovative wellness solutions within Adult Use & Wellness, offering consumers a diverse range of premium CBD, THC and minor cannabinoid formulations and formats across three distinct brands. #2 Overall National Oil Sales. (1) #2 Oil Brand in 2025
Slide 12: Metered Dose Inhalers: Precise, Discrete, Smoke-Free Innovation
Metered Dose Inhalers: Precise, Discrete, Smoke-Free Innovation • A smoke free, rapid onset innovation – shake and inhale for a fast onset without smoke or vapour. • An innovative way to unlock the potential of THC – smooth, direct to lung delivery for faster, more efficient absorption vs. ingested
Slide 13: Customers in Every Pharmaceutical Commercialization Path
Customers in Every Pharmaceutical Commercialization Path LONG TERM, PROFITABLE RELATIONSHIPS NOVEL DRUG APPLICATION (NDAs) ABBREVIATED NEW DRUG APPLICATION (ANDAs) FDA 505 B2 Completed first Pharma API sales in Q4 2021. Launched Dronabinol Pharmaceutical This page contains forward-looking statements
Slide 14: Canadian B2B and Pharma Platforms
Canadian B2B and Pharma Platforms MediPharm Labs provides manufacturing, packaging and supply services to many of the leading Cannabis companies in Canada and Globally. This includes full R&D development and supply agreements to GMP packaging and tolling services. These services extend to Pharmaceut
Slide 15: Sample of MediPharm Products in Active Clinical Trials
Sample of MediPharm Products in Active Clinical Trials Researcher Indication Phase Recent Milestone USC (Unive rsity of Southe rn Treatment of Alzheime r’s Agitati on Disorder Phase 2 FDA approval of Investi gat ional New Drug (IND) California) Keck School of Medi cine CTM delivere d, and enrollme n
Slide 16: Q3 2025 Highlights
Q3 2025 Highlights(1) Select highlights for the three month period ending September 30th, 2025 ● Revenue of $11.4 Million, an Increase of 17% compared to Q3 2024. Q3 2025 ● 83% Growth in International Medical Cannabis Revenue, Forming 56% of Total Revenue. Financials ● Gross Profit of $2.6 million,
Slide 17: Q3 2025 Financial Review: Revenues
Q3 2025 Financial Review: Revenues Revenue for Q3 was $11.4 million, an increase of $1.6 million or 17% versus prior year, driven by strong growth in our international medical cannabis business. Adjusted EBITDA(1) loss of $1.1 million in Q3 was impacted by product mix, while year-to-date adjusted EB
Slide 18: Q3 2025 Financial Review: Revenues
Q3 2025 Financial Review: Revenues • International medical cannabis revenue increased 83% year-over-year. • International medical cannabis revenue accounted for approximately 56% of total revenue in Q3 2025, up from 36% in Q3 2024. Q3 2025 Revenue By Channel (millions) International Medical Cannabis
Slide 19: Key Takeaways
Key Takeaways Pharmaceutical First International Revenues Strong Balance Corporate Development Cannabis Company Increasing Annually Sheet Opportunities >50% vs. Prior Year Full suite of GMP production licenses Growing, diversified full line Product Peer-leading Financials with a strong Continued exp
Slide 20: Thank You
THANK YOU investors@medipharmlabs.com
Slide 21: Additional Cautionary Notes
Additional Cautionary Notes (cont'd) ASSUMPTIONS. The Company made specific assumptions and relied on outside factors and considerations in this Presentation. See MediPharm’s filings, including the Q3 2025 MD&A, which are available on the SEDAR+ website at www.sedarplus.ca for full details, disclosu